New Delhi [India], November 25 (ANI): A day after Serum Institute of India (SII) Chief Executive Officer Adar Poonawalla asserted that its "soon to be widely available COVID-19 vaccine will offer protection up to 90 per cent in one type of dosage regime", Council of Scientific and Industrial
New Delhi [India], November 23 (ANI): Serum Institute of India (SII), CEO, Adar Poonawalla on Monday said that he is delighted to hear that Covidshield, soon to be widely available COVID-19 vaccine, will offer protection up to 90 per cent in one dosage regime and 62 per cent in another.
New Delhi [India], November 19 (ANI): Major drug marker Serum of Institute of India (SII) on Thursday said that the coronavirus vaccine, developed by teams at the University of Oxford, has been shown to trigger a robust immune response in healthy adults aged 56-69 and those over 70 years
New Delhi [India], November 12 (ANI): The Serum Institute of India (SII) and Indian Council of Medical Research (ICMR) have announced the completion of enrolment of phase 3 clinical trials for COVISHIELD in India.
Washington [US], October 10 (ANI): Antibodies in serum samples collected from patients infected with SARS-CoV during the 2003 outbreak effectively neutralised SARS-CoV-2 infection in cultured cells, according to a new study.
Washington [US], October 2 (ANI): US cosmetic giant Estee Lauder is all set to take one of its top products to International Space Station (ISS) with its recent tie-up with space agency National Aeronautics and Space Administration (NASA).
New Delhi [India], September 29 (ANI): Following a tweet by the Serum Institute of India, the Union Health Ministry on Tuesday said it disagrees with the mathematics which asked the government whether it has Rs 80,000 crore to buy and distribute COVID-19 vaccine to everyone in India.
Pune (Maharashtra) [India], September 29 (ANI): Serum Institute of India (SII) will produce up to an additional 100 million COVID-19 vaccine doses for India and low and middle-income countries (LMICs) in 2021.
Pune (Maharashtra) [India], September 19 (ANI): Serum Institute of India (SII) is all set to begin phase three trials of the Covishield Vaccine developed by AstraZeneca and Oxford University at Sassoon General Hospital in Pune, the hospital administration said on Saturday.
New Delhi [India], September 16 (ANI): The Drugs Controller General of India (DCGI) has allowed Serum Institute of India (SII) to restart its phase two and three clinical trials for COVID-19 vaccine after the pharma major submitted the recommendations of the Data Safety Monitoring Board (DSM
New Delhi [India], September 15 (ANI): Three COVID-19 vaccines are at a clinical trial stage in the country and two indigenous vaccine candidates have completed phase one trial, Indian Council of Medical Research (ICMR) DG Dr Balram Bhargava said on Tuesday.
New Delhi [India], September 12 (ANI): Hours after clinical trials for AstraZeneca and Oxford University coronavirus vaccine resumed on Saturday in the UK, pharma major Serum Institute of India (SII) said it will resume the trials in India once Drugs Controller General of India (DCGI) gives